QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH), (“Delcath” or the “Company”) an interventional oncology company focused on the treatment of primary and metastatic liver ...

Retrospective Study by University Hospital Southampton in metastatic uveal melanoma (mUM) patients with liver dominant disease shows hepatic disease control rate of 88.9%, hepatic response rate of ...

Delcath Systems Announces Publication of Subgroup Analyses of the Phase 3 FOCUS Study of Melphalan/Hepatic Delivery System in Patients with Unresectable Metastatic Uveal Melanoma Delcath Systems, Inc.

A subgroup analysis of the phase 3 FOCUS study (NCT02678572) shows that the Melphalan/Hepatic Delivery System (HDS; HEPZATO KIT) has a favorable benefit-risk profile for patients with metastatic uveal ...

TruVivo, the largest co-culture advancement in more than a decade, is a novel hepatic in vitro 2D+ system comprised of all-human cells that mimics the microarchitecture and functionality of the human ...

Melphalan/HDS treatment for patients with hepatic dominant metastatic uveal melanoma: Results from an expanded access program.